Last updated on February 2018

Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Brief description of study

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma.

The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .

Clinical Study Identifier: NCT02837757

Contact Investigators or Research Sites near you

Start Over

Antoine Thiery-Vuillemin, Dr

H pital Nord Franche-Comt
Montbéliard, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.